Specialized consulting at the intersection of drug development strategy, cross-border licensing, and China-West partnership — accelerating therapies from concept to global market.
NextLeap is a specialized advisory firm serving pharmaceutical and biotech companies navigating the complexities of drug development, licensing, and global commercialization.
With deep expertise bridging Chinese innovation ecosystems and Western markets, we provide strategic clarity at every stage — from early development through capitalization and launch.
Strategic planning across the full drug development lifecycle — from asset prioritization and indication selection to regulatory strategy and go-to-market roadmaps.
Structuring and negotiating in-licensing and out-licensing transactions across geographies, with expertise in IP valuation, term sheets, and milestone architecture.
Designing collaborative frameworks and alliance structures that align incentives, protect value, and enable seamless joint development or commercialization.
Identifying, qualifying, and cultivating strategic partners — from big pharma co-development agreements to regional distribution alliances and co-promotion deals.
Guiding the formation of new biotech ventures — from scientific concept to incorporated entity, with counsel on governance, founding team assembly, and early capitalization.
Strategic guidance on clinical trial design, development financing, investor positioning, and accessing capital markets to fund the path to approval and commercialization.
China has emerged as a powerhouse of pharmaceutical innovation, with cutting-edge biologics, novel small molecules, and breakthrough platforms developed at unprecedented speed. Navigating the bridge into Western markets demands rare expertise.
NextLeap was built for precisely this purpose. We understand both worlds with fluency — NMPA and FDA, CDE guidance and EMA requirements, Chinese investors and Western venture ecosystems.
Dual-track regulatory strategy for NMPA, FDA, and EMA approval pathways.
Established networks with Chinese innovators and Western licensees ready for partnership.
Deep understanding of negotiation styles, business practices, and expectations on both sides.
Structuring transactions that capture full asset value while enabling rapid global access.
We begin with a thorough assessment of your assets, objectives, and competitive landscape to identify the highest-value strategic opportunities.
We develop a tailored strategic roadmap — including deal structures, partner targets, regulatory plans, and capitalization frameworks.
We work hands-on to source partners, structure transactions, and lead negotiations — turning strategy into signed agreements.
We support post-deal integration, milestone management, and ongoing alliance governance to ensure long-term value is captured.
20+ years at the intersection of Chinese biopharma innovation and Western market access. Deep networks spanning NMPA, FDA, and EMA pathways, with a track record of closing landmark cross-border licensing and partnership transactions.
Specialist in clinical and medical strategy across drug development lifecycles. Expertise in IND/NDA submissions, Phase I–III trial design, and translating complex science into compelling regulatory and commercial narratives.
The firm advised on a landmark out-licensing transaction connecting a leading Chinese biotech with a US partner, advancing a novel oncology asset toward IND filing and global development.
A deep dive into how NextLeap is reshaping cross-border biopharma strategy and what it takes to build bridges between Chinese innovation and Western markets.
Whether you're exploring a licensing opportunity, seeking a strategic partner, or building a new company — we'd like to hear from you.